Epstein Secrets

et, 3 ni floor San Francisco, CA 94103 Dear Mr. Tamaru: We have completed our analysis of the fair market value of the common equity of AliphCom ("Aliph" or the "Company") on a per share basis (the "Subject Interest") as of June 20, 2011 (the "Valuation Date"). We understand that our valuation of th

median discounts from the restricted stock studies. SUMMARY OF RESTRICTED STOCK STUDIES [SEC Studies (non-reporting OTC companies [Gelman Study [Moroney Study $Maher Study [Trout Study [Standard Research Consultants Study [Silber Study [Management Planning, Inc. Study [FMV Study [Hertzel - Smith Stud

et, 3 ni floor San Francisco, CA 94103 Dear Mr. Tamaru: We have completed our analysis of the fair market value of the common equity of AliphCom ("Aliph" or the "Company") on a per share basis (the "Subject Interest") as of June 20, 2011 (the "Valuation Date"). We understand that our valuation of th

median discounts from the restricted stock studies. SUMMARY OF RESTRICTED STOCK STUDIES [SEC Studies (non-reporting OTC companies [Gelman Study [Moroney Study $Maher Study [Trout Study [Standard Research Consultants Study [Silber Study [Management Planning, Inc. Study [FMV Study [Hertzel - Smith Stud

et, 3 ni floor San Francisco, CA 94103 Dear Mr. Tamaru: We have completed our analysis of the fair market value of the common equity of AliphCom ("Aliph" or the "Company") on a per share basis (the "Subject Interest") as of June 20, 2011 (the "Valuation Date"). We understand that our valuation of th

median discounts from the restricted stock studies. SUMMARY OF RESTRICTED STOCK STUDIES [SEC Studies (non-reporting OTC companies [Gelman Study [Moroney Study $Maher Study [Trout Study [Standard Research Consultants Study [Silber Study [Management Planning, Inc. Study [FMV Study [Hertzel - Smith Stud